Antibodies, Monoclonal, Humanized
"Antibodies, Monoclonal, Humanized" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
| Descriptor ID |
D061067
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060 D12.776.124.790.651.114.224.060 D12.776.377.715.548.114.224.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Humanized".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Humanized".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Humanized" by people in this website by year, and whether "Antibodies, Monoclonal, Humanized" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 8 | 8 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 11 | 11 |
| 2009 | 0 | 11 | 11 |
| 2010 | 0 | 13 | 13 |
| 2011 | 5 | 15 | 20 |
| 2012 | 7 | 8 | 15 |
| 2013 | 6 | 6 | 12 |
| 2014 | 11 | 8 | 19 |
| 2015 | 4 | 9 | 13 |
| 2016 | 4 | 13 | 17 |
| 2017 | 7 | 12 | 19 |
| 2018 | 10 | 10 | 20 |
| 2019 | 17 | 12 | 29 |
| 2020 | 18 | 17 | 35 |
| 2021 | 24 | 9 | 33 |
| 2022 | 8 | 21 | 29 |
| 2023 | 5 | 26 | 31 |
| 2024 | 29 | 15 | 44 |
| 2025 | 23 | 7 | 30 |
| 2026 | 16 | 2 | 18 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet. 2026 May 23; 407(10543):2027-2039.
-
Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer. Anticancer Res. 2026 May; 46(5):2445-2453.
-
Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2026 Apr 28; 10(8):2698-2710.
-
Intralesional secukinumab for localized, recalcitrant hidradenitis suppurativa: a case series of rapid symptom relief. J Dermatolog Treat. 2026 Dec; 37(1):2660529.
-
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clin Cancer Res. 2026 Apr 15; 32(8):1454-1461.
-
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia. N Engl J Med. 2026 Apr 09; 394(14):1388-1398.
-
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial. Nat Commun. 2026 Mar 14; 17(1).
-
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study. Blood Adv. 2026 Mar 10; 10(5):1564-1575.
-
Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children. JAMA Pediatr. 2026 Mar 01; 180(3):314-324.
-
Intracoronary Imaging and Transcriptomic Characteristics Before and After Maximum Lipid-Lowering Therapy: YELLOW-III Study of Evolocumab and Maximum Statin Therapy in Chronic Coronary Disease. JACC Cardiovasc Imaging. 2026 Apr; 19(4):516-534.